946426-88-6

Basic information

• Product Name: 4-ISOXAZOLECARBOXYLIC ACID, 5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-, METHYL ESTER
• Synonyms: 4-ISOXAZOLECARBOXYLIC ACID, 5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-, METHYL ESTER;Methyl 5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-carboxylate;Methyl 5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole-4-carboxylate
• CAS NO: 946426-88-6
• Molecular Formula: C₁₄H₁₁Cl₂NO₃
• Molecular Weight: 312.14804
• Mol File: 946426-88-6.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 434.9±45.0 °C(Predicted)
• Appearance: /
• Density: 1.415±0.06 g/cm3(Predicted)
• PKA: -5.92±0.50(Predicted)
• CAS DataBase Reference: 4-ISOXAZOLECARBOXYLIC ACID, 5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-, METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-ISOXAZOLECARBOXYLIC ACID, 5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-, METHYL ESTER(946426-88-6)
• EPA Substance Registry System: 4-ISOXAZOLECARBOXYLIC ACID, 5-CYCLOPROPYL-3-(2,6-DICHLOROPHENYL)-, METHYL ESTER(946426-88-6)

Safety Data

• Hazardous Substances Data: 946426-88-6(Hazardous Substances Data)

Usage

General Description

4-Isoxazolecarboxylic acid, 5-cyclopropyl-3-(2,6-dichlorophenyl)-, methyl ester is a chemical compound that consists of an isoxazole ring, a cyclopropyl group, a dichlorophenyl group, and a methyl ester group. It is used in the synthesis of pharmaceuticals and agrochemicals as an intermediate or building block. 4-Isoxazolecarboxylic acid, 5-cyclopropyl-3-(2,6-dichlorophenyl)-, methyl ester has potential biological activity and is being studied for its potential use as an antiviral, anti-inflammatory, or anti-cancer agent. Additionally, it may have potential uses as a pesticide or insecticide. The specific properties and uses of this compound may vary depending on its formulation and application.

Upstream product

• 447-61-0 2-Trifluoromethylbenzaldehyde 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 1260837-59-9 methyl 3-cyclopropyl-2-oxopropanoate 
• 91979-30-5 2,6-dichloro-benzaldehyde chloroxime 
• 74467-04-2 N-hydroxy-2-(trifluoromethyl)benzene-1-carbonimidoyl chloride 
• 24922-02-9 Ethyl 3-cyclopropyl-3-oxopropionate 
• 74467-00-8 N-[[2-(trifluoromethyl)phenyl]methylidene]hydroxylamine 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 

Downstream Products

• 946426-89-7 4-(hydroxymethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazole 
• 1103500-20-4 TERN-101 
• 1103500-82-8 6-{4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]piperidin-1-yl}-1-methyl-1H-indole-3-carboxylic acid methyl ester 
• 946426-94-4 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole 
• 1296211-56-7 4-[5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-ylmethoxy]piperidine-1-carboxylic acid tert-butyl ester 
• 1103501-11-6 5-cyclopropyl-3-(2,6-dichlorophenyl)-4-((piperidin-4-yloxy)methyl)isoxazole 

Relevant articles and documents

PPARs-FXR multi-target micromolecular agonist as well as preparation method and application thereof

The invention discloses a PPARs-FXR multi-target micromolecule agonist and a preparation method and application thereof, the structure is shown in a general formula I, and the definition of each substituent group is shown in the description and claims. Th

Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen-induced hepatotoxicity

Acetaminophen (APAP) overdose is a leading cause of acute hepatic failure and liver transplantation, while the existing treatments are poorly effective. Therefore, it is necessary to develop effective therapeutic drugs for APAP-induced hepatotoxicity. Farnesoid X receptor (FXR) is a potential target for the treatment of liver disease, and the activation of FXR protects mice against APAP-induced hepatotoxicity. Compound 5, a glycine-conjugated derivative of FXR agonist 4, was designed to extend the chemical space of existing FXR agonists. Molecular modeling study indicated that compound 5 formed hydrogen bond network with key residues of FXR. Moreover, compound 5 (10?mg/kg) revealed better protective effects against APAP-induced hepatotoxicity than parent compound 4 (30?mg/kg). Further mechanical research indicated that compound 5 regulated the expressions of genes related to FXR and oxidative stress. These findings suggest that compound 5 is a promising FXR agonist suitable for further research, and it is the first time to verify that the glycine-conjugated derivative five exerted better protective effects than its parent compound.

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.